Olympus To Step Up Endoscope Business In China
This article was originally published in PharmAsia News
Executive Summary
Top endoscope maker Olympus recently disclosed that its capsule endoscope is currently under review with China's State FDA and is expected to enter the China market as early as late this year. The capsule endoscope will represent a milestone product for the firm's health care business to open up China's market. Even though digital cameras and endoscopes make up one-third each of Olympus' business, the company is only known in China for its cameras. Thus, the firm's primary and most pressing task is to build up brand awareness in the country. To quickly occupy the market, Olympus has established main branches in Beijing, Shanghai and Guangzhou as well as a network of 31 representative offices across the country. It will next target gastroenterology and general surgery as two focus areas. (Click here for more - Chinese Language)
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.